Back to Agenda
Session 3 / Venue 6: Now, Let’s have a Direct Discussion with Patients for the Drug Discovery and Development
Session Chair(s)
Hiroshi Watanabe, MD, PhD
Vice President
Hamamatsu University School of Medicine, Japan
Everyone wishes to deliver safer and more effective drugs as early as possible to patients. To achieve this, it is important to learn about the patients’ wishes and take proper action based on patients’ requirements during drug development. Although the chance to establish face-to-face communication with patients is increasing, it is still rare for people working in pharmaceutical industries. This session, started last year, continues to focus on what we should learn from patients for future drug development. For example, the priority of the patients’ needs or wishes, the economic stumbling blocks in daily life, other difficulties for the patients and the issues of corporate activities among stakeholders. Based on the discussion from each point of view, the patients, the government, the medical profession and the pharmaceutical industries, we would like to seek the possibility of mutual and fruitful collaboration for future “Drug Discovery and Development” & “Drug Fostering and Evolution”.
Speaker(s)
Eiko Uchida
Breast Cancer Patient Support Group BOUGAINVILLA, Japan
Founder and Chief
Noriko Murakami
Pulmonary Hypertension Association (PHA), Japan
Founder and President
Drug Information and Patients
Tomiko Tawaragi
RAD-AR, Japan
Chief Director
Patient-Focused Drug Development
Kazumichi Kobayashi, RPh
Otsuka Medical Devices Co., Ltd., Japan
Executive Deputy President (Board Member)
Have an account?